1262052-36-7

1262052-36-7 structure

Name: Rifampicin-d3
Chemical Name: Rifampicin-d3
CAS Number: 1262052-36-7
Molecular Formula: C₄₃H₅₅D₃N₄O₁₂
Molecular Weight: 825.959
Catalog: Signaling Pathways Anti-infection Bacterial
Create Date: 2021-05-10 19:30:23
Modify Date: 2024-04-06 16:18:44
Rifampicin-d3 (Rifampin-d3) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities[1][2].

Name	Rifampicin-d3
Synonyms	2,7-(Epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[(E)-[[4-(methyl-d3)-1-piperazinyl]imi no]methyl]-, (2S,12E,14E,16S,17S,18R,19R,20R,21S,22S,23S,24E)- (7S,9E,11S,12S,13S,14R,15R,16R,17S,18S,19E,21E)-2,15,17,27,29-Pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-{[4-(2H3)methyl-1-piperazinyl]imino}methyl]-6,23-dioxo-8,30-dioxa-24-az atetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl acetate Rifampicin-d3

Description	Rifampicin-d3 (Rifampin-d3) is the deuterium labeled Rifampicin. Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti-influenza virus activities[1][2].
Related Catalog	Signaling Pathways >> Anti-infection >> Influenza Virus Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7. [3]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2. [4]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61. [5]. Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6(2):169-74.